- POSITIVE
Quarterly Revenue Emcure Pharma Sep-2026 Quarterly Revenue is Rs 1,702 Cr which is growth of 32.6% YoY.
- POSITIVE
Quarterly Net Profit Emcure Pharma Sep-2026 Quarterly Net Profit is Rs 248 Cr which is growth of 111.2% YoY.
2334.80-4.60(-0.20%)
263.9K
NSE+BSE Volume
NSE 18 Nov, 2026 3:31 PM
Emcure Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Forecaster Analyst Estimates for Emcure Pharma share price target, revenues, EPS, net income and more
Emcure Pharma quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,701.5 | 1,476 | 1,494.6 | 1,556.6 | 1,283.4 | 1,118.1 | 1,300.6 | 1,048.2 | 1,159.6 | 1,002.8 | 936.7 | 922.7 | 918.1 | ||
Operating Exp. | 1,271.7 | 1,111.4 | 1,096.1 | 1,117.8 | 1,036 | 868.6 | 1,033.6 | 904.4 | 952.5 | 855.1 | 796.2 | 745.7 | 788.4 | |
Operating Profit | 396.3 | 339.6 | 371.7 | 300.5 | 224.6 | 228 | 244.6 | 124.4 | 152.2 | 115.2 | 106.3 | 124.5 | 99.6 | |
Operating Profit Margin % | 23.76% | 23.40% | 25.32% | 21.19% | 17.82% | 20.79% | 19.14% | 12.09% | 13.77% | 11.87% | 11.78% | 14.31% | 11.22% | |
Depr. | 65 | 63.2 | 63 | 62.1 | 61.7 | 59.8 | 56.9 | 56.7 | 56.3 | 55.1 | 39.5 | 78.7 | 48 | |
Interest | 32.4 | 32.8 | 36.9 | 33.2 | 27.7 | 20.5 | 24.1 | 19.9 | 31.4 | 37.6 | 56.2 | 17.7 | 45.9 | |
Profit Before Tax | 332.4 | 268.7 | 306.3 | 314.4 | 157.9 | 165.7 | 186.1 | 67.3 | 119.4 | 55.1 | 35.5 | 80.7 | 35.9 | |
Tax | 84 | 68.6 | 72.6 | 55.5 | 40.3 | 42.9 | 46.5 | 17.1 | 32.4 | 14.6 | 6.5 | 12.4 | 8.6 | |
Net Profit | 248.4 | 200.1 | 233.7 | 258.9 | 117.6 | 122.8 | 139.6 | 50.2 | 86.9 | 40.5 | 29 | 68.3 | 27.3 | |
EPS Adj. latest | 13.1 | 10.6 | 12.3 | 13.6 | 6.2 | 6.5 | 7.4 | 2.7 | 4.6 | 2.1 | 1.5 | 3.6 | 1.4 | |
Net profit TTM | 941.1 | 810.3 | 733 | 638.8 | 430.2 | 399.5 | 317.1 | 206.6 | 224.6 | 165.1 | 160.8 | - | - | |
Basic EPS TTM | 49.6 | 42.7 | 38.7 | 33.7 | 22.7 | 21.1 | 16.7 | 10.9 | 11.9 | 9.1 | 8.9 | - | - | |
Earnings Transcripts | ||||||||||||||
AI Summary | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Emcure Pharma competitor comparison and performance snapshot within industry
Emcure Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Annual Revenue Emcure Pharma Mar-2026 Annual Revenue is Rs 5,453 Cr which is growth of 21.2% YoY.
- POSITIVE
Annual Net Profit Emcure Pharma Mar-2026 Annual Net Profit is Rs 733 Cr which is growth of 131.1% YoY.
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
21.2%
2Y CAGR
22.5%
3Y CAGR
19%
5Y CAGR
10.8%
7Y CAGR
11.5%
10Y CAGR
9.6%
Total Revenue Annual growth is higher than historical averages.
Net Profit Ann.
1Y CHG
131.2%
2Y CAGR
113.5%
3Y CAGR
66%
5Y CAGR
11.8%
7Y CAGR
14.5%
10Y CAGR
8.7%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
10.3%
2Y CAGR
16.1%
3Y CAGR
15.6%
5Y CAGR
11.3%
7Y CAGR
11.8%
10Y CAGR
10.3%
Operating Expenses Annual Cr growth is lower than historical averages.
Emcure Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund Emcure Pharma Mar-2026 Total Shareholders Fund is Rs 3,711 Cr which is growth of 22.7% YoY.
- POSITIVE
Total Assets Emcure Pharma Mar-2026 Total Assets is Rs 6,914 Cr which is growth of 27.7% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
26.3% | 10% | 3,710.6 | 3,024.4 | 1,935.1 | 1,841.9 | 1,712.5 | 2,301.8 | 1,914.6 | 1,777.5 | 1,410.6 | 1,226.9 | 1,087.6 | ||
Minority Interest Liability Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
6.4% | 3.9% | 936 | 672.6 | 691.7 | 777.7 | 676.6 | 772.2 | 576.9 | 526.7 | 450.7 | 478.5 | 512.7 | ||
4.3% | 4.9% | 2,267.4 | 1,719.2 | 2,130.1 | 1,996.3 | 1,934.1 | 1,789.2 | 1,379.8 | 1,273.3 | 1,267.8 | 1,002.3 | 1,001.2 | ||
Total Capital Plus Liabilities Ann. | 14.4% | 7.3% | 6,914 | 5,416.1 | 4,756.9 | 4,615.9 | 4,323.2 | 4,863.2 | 3,871.2 | 3,577.6 | 3,129.1 | 2,707.7 | 2,601.4 | |
3.6% | 5% | 1,876.1 | 1,858.2 | 1,824.6 | 1,685.8 | 1,546.6 | 1,470 | 1,492.1 | 1,505.9 | 1,360.9 | 1,168.8 | 961.3 | ||
16.1% | 7.9% | 3,873 | 2,956.1 | 2,633.5 | 2,476.3 | 2,187.1 | 2,647.7 | 2,063.6 | 1,939.3 | 1,872.7 | 1,703.7 | 1,494.5 | ||
12.4% | 6.5% | 3,041.1 | 2,460.1 | 2,123.4 | 2,139.5 | 2,136.1 | 2,215.5 | 1,807.6 | 1,638.3 | 1,256.4 | 1,004 | 1,106.9 | ||
Total Assets Ann. | 14.4% | 7.3% | 6,914 | 5,416.1 | 4,756.9 | 4,615.9 | 4,323.2 | 4,863.2 | 3,871.2 | 3,577.6 | 3,129.1 | 2,707.7 | 2,601.4 | |
Contingent Liabilities plus Commitments Ann. | 42.2% | 33.3% | 191.6 | 303.7 | 244.1 | 66.6 | 89.1 | 45.5 | 52.4 | |||||
Bonus Equity Share Capital Ann. | - | - | ||||||||||||
Non Current Investments Unquoted Book Value Ann. | 27.3% | 10.5% | 1,424.3 | 677.7 | 684 | 690 | 563.4 | 863.7 | 407.7 | 310.6 | 305 | 298.1 | 290.6 | |
Current Investments Unquoted Book Value Ann. | - | - |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Assets Ann.
1Y CHG
27.7%
2Y CAGR
20.6%
3Y CAGR
14.4%
5Y CAGR
7.3%
7Y CAGR
9.9%
10Y CAGR
10.3%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
31.9%
2Y CAGR
3.2%
3Y CAGR
4.3%
5Y CAGR
4.9%
7Y CAGR
8.6%
10Y CAGR
8.5%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
22.7%
2Y CAGR
38.5%
3Y CAGR
26.3%
5Y CAGR
10%
7Y CAGR
11.1%
10Y CAGR
13.1%
Total ShareHolders Funds Annual growth is stable compared to historical averages.
Emcure Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Book Value Per Share Emcure Pharma Mar-2026 Book Value Per Share is 196 Rs which is growth of 22.6% YoY.
- POSITIVE
ROE Emcure Pharma Mar-2026 ROE is 20% which is growth of 9.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BVSH Ann. | 24.3% | 9% | 195.7 | 159.6 | 106.8 | 101.8 | 94.7 | 127.3 | 105.9 | 98.3 | 78 | 67.8 | 60.1 | |
RoA Ann. % | 45.2% | 4.2% | 10.60% | 5.85% | 3.38% | 3.46% | 10.33% | 8.64% | 4.52% | 7.92% | 7.75% | 8.01% | 12.22% | |
ROE Ann. % | 31.5% | 1.6% | 19.75% | 10.48% | 8.31% | 8.69% | 26.09% | 18.26% | 9.15% | 15.95% | 17.21% | 17.69% | 29.23% | |
ROCE Ann. % | 16.8% | 0.6% | 23.40% | 14.62% | 14.28% | 14.70% | 31.87% | 22.74% | 16.29% | 23.06% | 25.17% | 24.78% | 32.96% | |
Total Debt to Total Equity Ann. | -23.7% | -7.8% | 0.4 | 0.2 | 0.7 | 0.9 | 0.9 | 0.6 | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
ROE Ann. %
1Y CHG
88.5%
2Y CAGR
54.2%
3Y CAGR
31.5%
5Y CAGR
1.6%
7Y CAGR
3.1%
10Y CAGR
-3.8%
ROE Annual % is growing faster than historical averages.
RoA Ann. %
1Y CHG
81.2%
2Y CAGR
77.1%
3Y CAGR
45.2%
5Y CAGR
4.2%
7Y CAGR
4.3%
10Y CAGR
-1.4%
RoA Annual % is growing faster than historical averages.
Current Ratio Ann.
1Y CHG
-7.1%
2Y CAGR
14%
3Y CAGR
5.7%
5Y CAGR
1.6%
10Y CAGR
1.7%
Current Ratio Annual is falling faster than historical averages.
Emcure Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Cash From Operating Activity Emcure Pharma Mar-2026 Cash From Operating Activity is Rs 424 Cr which is growth of -24.1% YoY.
- NEGATIVE
Net Cash Flow Emcure Pharma Mar-2026 Net Cash Flow is Rs 1 Cr which is growth of -98.3% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-5.7% | -11.4% | 423.6 | 558.3 | 585 | 505.4 | 427.7 | 774.9 | 385.3 | 371.2 | 401.1 | 325.3 | 250.7 | ||
Cash from Investing Act. Ann. | - | - | -948.1 | -435.6 | -171.1 | -270.4 | -189 | -831.2 | -164.8 | -275.8 | -287.3 | -299.6 | 399.3 | |
Cash from Financing Act. Ann. | - | 76.2% | 525.8 | -49.3 | -287.8 | -54.5 | -343 | 31 | -45.9 | -53.5 | -216.8 | -58.8 | 772 | |
-81.2% | - | 1.2 | 73.4 | 126.2 | 180.4 | -104.3 | -25.3 | 174.6 | 42 | -103 | -33.1 | 1,422 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-24.1%
2Y CAGR
-14.9%
3Y CAGR
-5.7%
5Y CAGR
-11.4%
7Y CAGR
1.9%
10Y CAGR
5.4%
Cash from Operating Activity Annual is falling faster than historical averages.
Cash from Financing Act. Ann.
5Y CAGR
76.2%
10Y CAGR
-3.8%
Cash from Financing Annual Activity growth is higher than historical averages.
